

National Oesophago-Gastric Cancer Audit

Mid Yorkshire Hospitals NHS Trust

West Yorkshire and Harrogate, Cancer Alliance

Management of High Grade Dysplasia patients

Time period: 2018-22

		Cancer Alliance		National
Number of High Grade Dysplasia patients in audit	18			1120
		Cancer Alliance		National
Method of Diagnosis				
– First diagnosis confirmed by second pathologist	N/A	76.5%	90.0%	
Treatment planning				
– HGD plan discussed at MDT	N/A	88.9%	93.0%	
– Treatment plan for active treatment	N/A	83.3%	82.0%	
First treatment				
– Endoscopic therapy (such as endoscopic resection)	N/A	83.3%	78.0%	
– Surveillance	N/A	5.6%	11.0%	

NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.

Management of oesophago-gastric cancer patients

Time period: 2020-2022

	Organisation		National
Number of oesophago-gastric (OG) cancer patients in audit	195		19,865
Case ascertainment for OG cancer (%)	85-100%		
Method of Diagnosis			
– Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations	28	15.1%	13.1%
– Patients with referral source reported as unknown	8	4.1%	1.4%
Pre-treatment staging of cancer			
– Patients having staging CT scan recorded	175	89.7%	94.0%
Treatment planning			
– Patients having a plan for curative treatment	83	42.6%	37.2%
– Patients having a plan for non-curative treatment	112	57.4%	62.8%
– Patients with non-curative plans having chemotherapy or radiotherapy	N/A		34.7%